Undernutrition results in weakness, apathy and decreased quality of life. One cause for such malnutrition is cancer cachexia. Gain in weight, though not necessarily in lean body mass, can be achieved in such patients. Quality of life can be enhanced by improving nutrition in chronically ill patients without cancer1. Can quality of life usefully be improved by artificial nutrition in patients dying of cancer and unable to maintain adequate food intake? And if it can, despite not prolonging life by more than a few weeks, is nutrition support justified?
The use of artificial feeding by tube feed, gastrostomy or home parenteral nutrition varies widely throughout the world. This is particularly true ofhome parenteral nutrition2, which for this indication is used much less in the UK than in the USA, Italy, the Netherlands and Belgium, but the difference exists also for the less expensive home enteral feeding techniques3. Those who seldom use these techniques argue that they may actually worsen quality of life because any benefit in well-being brought about by improved nutrition is likely to be outweighed by the burden of the treatment in the last few months of life, that they may prolong dying rather than useful life, and that they are a poor use of scant healthcare funds. They might add that, at a time when the widespread use of artificial nutritional support (1% of healthcare costs in the USA) is coming under criticism4, such treatments should be used only if prospective randomized controlled trials prove efficacy. Those who advocate the treatments believe that the techniques are quite easy to learn, are well accepted by the patients and their carers, maintain or improve quality of life and provide a positive approach to the patient's valuable remaining life. From this standpoint, while they might agree that nutritional support should be offered by the cheapest way acceptable to the patient, they might question whether cost should ethically be allowed to determine the approach to care. With imaginative organization such techniques can be delivered to patients at home. If patients could be kept stronger longer, perhaps their needs for hospital or hospice care might be reduced and the costs recouped. They might say that no randomized trials are needed to prove the efficacy of food in the presence of greatly reduced nutrient intake.
On p 597 of this issue, Dr Pironi and colleagues report an audit of practice in the Bologna district, where a well established care-at-home service includes supervision of nutrition support for cancer patients. Criteria for accepting 141 -U 0b76 ( i patients for such treatment include grossly-4if ite food intake, moderate weight loss or fairly low body mass index, and a predicted life expectancy of more than six weeks; the aim is thus to select patients who might die as a result of their undernutrition before they were predicted to die from their cancer. The approach emphasizes nasoenteric feeding but home parenteral feeding is used much more than elsewhere in Italy or in Europe. The patients treated in Bologna seem to have shorter life expectancy than cancer patients in the USA, where the mean at start of nutritional support is about six months5. Although many clinicians, particularly in the UK, will not be immediately persuaded by the Bologna approach, and may indeed be very concerned by the implied increase in caseload, the Bologna workers do provide useful data on the difficulties of predicting outcome in cancer and a guide to the implications of such an approach. Some readers will be concerned, as the authors themselves hint, about the level of informed consent to these treatments, in that so few of the patients knew their diagnosis or prognosis. It is far from clear to me that, had they been more completely informed, they would have consented to invasive feeding techniques but to concentrate too much on this issue would be to fail to address the main debate stimulated by this provocative paper. Although attempts have been made to quantify improvements in quality of life among undernourished patients treated nutritionally, this remains a difficult and inexact science. The present paper shows little improvement in the Karnofsky scale during the first month of treatment, when the advantages of improved nutrition might have a chance of outweighing the decline in well-being consequent upon their cancer. However, it may be that the Karnofsky scale, an index of function and mobility, is not the best instrument to document changes in quality of life in these circumstances6. Furthermore, though most patients were not shown to improve with treatment we do not know whether the patients would have fared worse without the treatment. The cost of the treatments is large, and life clearly is not greatly lengthened by it. We need a well-designed randomized control trial, and I very much hope that the Bologna group, or another like it, will take up the challenge so that, in perhaps five years' time, they might be in a position to persuade sceptics like me that this approach needs to be applied so extensively. Meanwhile it is clear that terminal care teams should consider how they might link with nutritionists to provide the simplest and most comforting approach to improving well-being through nutrition. Good nursing practices, supported by a team approach (including ii Y O the patients and carers) to imaginative provision of food and nutritious drinks, should be a useful start. 
